ArticleJournal of dental sciences2026
Development of a risk scoring system for predicting post-extraction medication-related osteonecrosis of jaws: A derivation and validation cohort study.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Although risk factors for medication-related osteonecrosis of the jaw (MRONJ) are known, clinical assessment prior to dental extraction remains largely subjective. We aimed to develop and externally validate a simple clinical risk scoring system to predict post-extraction MRONJ in osteoporotic patients receiving antiresorptive therapy (ART) and support evidence-based clinical decision-making. Materials and methods: This retrospective cohort study used a derivation cohort (N = 1067 extractions, 2003-2022) to develop a 5- to 16-point risk score system based on five predictors (age ≥75, ART duration ≥24 months, bisphosphonate use, drug interruption Results: MRONJ prevalence was lower in the validation cohort (2.2% vs. 24.5%; Conclusion: The model demonstrates good discrimination and excellent "rule-out" utility in a real-world, low-prevalence setting, identifying low-risk patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.